| NCT03514407 |
A Study of INCB059872 in Relapsed or Refractory Ewing Sarcoma |
Recruiting |
Relapsed Ewing Sarcoma |
INCB059872 |
| NCT03600649 |
Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing Sarcoma |
Recruiting |
Ewing Sarcoma |
SP-2577 |
| EUCTR2018-000469-35 |
A pilot study to assess the safety, tolerability, dose finding and efficacy ORY-1001 in combination with platinum-etoposide chemotherapy in patients with relapsed, extensive-stage disease small cell lung cancer |
Ongoing |
Relapsed, extended-stage disease small cell lung cancer |
ORY-1001 |
| EUCTR2017-002838-23 |
Randomized, double-blind, placebo-controlled, 3-arm, 36 weeks parallel-group study to evaluate the safety and tolerability of ORY-2001 in patients with Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis |
Authorised |
Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis |
ORY2001 |
| NCT03505528 |
An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast Cancer |
Recruiting |
Metastatic Breast Cancer |
Nanoparticle albumin-bound paclitaxel| Phenelzine Sulfate |
| NCT02712905 |
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies |
Recruiting |
Solid Tumors and Hematologic Malignancy |
INCB059872| ATRA| azacitidine| nivolumab |
| NCT03895684 |
Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors |
Not yet recruiting |
Advanced Solid Tumors |
SP-2577 Seclidemstat |
